Antiaging Vaccines Targeting Senescent Cells

Area of Science:

• Cellular senescence
• Immunotherapy
• Metabolic disorders

Background:

• Senescent cells (SCs) contribute to aging disorders but also play roles in tissue repair.
• Current senolytic and senomorphic drug development faces challenges in efficacy, targeting specificity, and side effects.
• Senescent cells express specific biomarkers, offering potential targets for therapeutic intervention.

Purpose of the Study:

• To explore novel strategies for selectively targeting senescent cells (SCs) in aging-associated pathologies.
• To evaluate the therapeutic potential of targeting GPNMB, a newly identified senescence biomarker, in mouse models.
• To assess the impact of GPNMB-targeted therapies on atherosclerotic plaque burden and metabolic dysfunction.

Main Methods:

• Development of a peptide vaccine targeting GPNMB on senescent endothelial cells.
• Administration of the GPNMB vaccine to mouse models of obesity and atherosclerosis.
• Evaluation of atherosclerotic plaque burden, glucose metabolism, and glucose intolerance.
• Consideration of passive immunization with monoclonal antibodies against GPNMB as an alternative.

Main Results:

• The GPNMB-targeting peptide vaccine reduced atherosclerotic plaque burden in mouse models.
• Vaccine treatment improved metabolic dysfunction, including glucose intolerance, in obese and atherosclerotic mice.
• Previous approaches using CAR T-cells targeting urokinase-type plasminogen activator receptor and a vaccine targeting CD153 also showed promise in improving glucose metabolism.

Conclusions:

• Targeting GPNMB-expressing senescent cells with a peptide vaccine is a promising strategy for treating atherosclerosis and metabolic dysfunction.
• Careful control of vaccine activity is crucial for human translation due to GPNMB's roles in normal physiology.
• Passive immunization with anti-GPNMB monoclonal antibodies presents a potentially safer alternative for therapeutic intervention.